Skip to main content

Microbial DNA Specialist OpGen Pockets $23.6M in Series A VC Cash

NEW YORK (GenomeWeb News) — OpGen has received $23.6 million in Series A private-equity financing that it plans to use to “develop commercial instrumentation systems for the clinical microbiology marketplace.”   
 
OpGen, a Madison, Wisc.-based company specializing in analyzing microbial DNA, also said it is looking for a new chief executive.
 
The cash came from three new venture capital investors, including CHL Medical Partners, Highland Capital Partners, and Versant Ventures. Existing investor Mason Wells also contributed in the round.
 
OpGen said it has added to its board of directors one investor each from Highland and Versant. Ron Lennox from CHL will become chairman of OpGen’s board, the company said. Lennox will be joined on the board by Corey Mulloy and Bijan Salehizadeh from Highland, and Versant's Brian Atwood.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.